Madrigal Pharmaceuticals, Inc.
MDGL
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor- agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steaā¦ read more
Healthcare
Biotechnology
19 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$444.83
Price+1.39%
$6.10
1Y
Price
Market Cap
$10.103b
Large
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-15.5%
EBITDA Margin-18.2%
Net Profit Margin-41.4%
Free Cash Flow Margin-15.5%
EBITDA Margin-18.2%
Net Profit Margin-41.4%
Free Cash Flow MarginRevenue
$958.403m
+432.1%
1y CAGR+144.0%
3y CAGR+108.0%
5y CAGREarnings
-$288.284m
+38.1%
1y CAGR-4.4%
3y CAGR-8.8%
5y CAGREPS
-$12.85
+41.2%
1y CAGR+5.2%
3y CAGR-0.5%
5y CAGRBook Value
$602.689m
$1.260b
Assets$656.900m
Liabilities$354.361m
DebtDebt to Assets
28.1%
-1.3x
Debt to EBITDAFree Cash Flow
-$190.020m
+58.4%
1y CAGR-8.9%
3y CAGR-12.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company